Heat Shock Protein 90 (HSP90) is an ATP-dependent molecular chaperone that assists in correct folding Of a Wide variety Of ‘client’ proteins (Androgen Receptor (AR), AKT, HER2 and CDK4).
ATI 3387 (AT) is a fragment derived, second-generation novel potent non-ansamycin HSP90 inhibitor (Kd:O.71 nM)1 with good tissue distribution, excellent in vivo anti-tumor activity and long tumor half life in preclinical models (65-78 hours).
ATI 3387 demonstrated anti-tumor activity in preclinical castration-resistant prostate cancer (CRPC) models2 and ho ds promise as a therapeutic agent by simultaneously down-regulating multiple aberrant signalling pathways.
View further details below
2014: ESMO Phase 1/2 of AT13387, HSP90 Inhibitor, in combo with abiraterone acetate and prednisone